Palisade Bio's PALI-2108, a PDE4 inhibitor, targets Crohn’s disease and ulcerative colitis, with patent allowance in China.
Quiver AI Summary
Palisade Bio, Inc. has announced that the China National Intellectual Property Administration has issued a Notice of Allowance for a patent covering PALI-2108, a novel phosphodiesterase-4 inhibitor targeting the terminal ileum and colon for treating fibrostenotic Crohn’s disease and ulcerative colitis. This development is significant for addressing unmet medical needs in these conditions within the rapidly growing inflammatory bowel disease market in China, projected to reach nearly $1 billion by 2030. The allowed patent, extending potentially until 2045, is crucial for protecting the company's intellectual property as it advances PALI-2108 through clinical trials. The CEO, J.D. Finley, emphasized the importance of strengthening their global intellectual property portfolio and expressed confidence in PALI-2108’s potential, especially with upcoming clinical milestones over the next 12-18 months.
Potential Positives
- PALI-2108 is the first and only PDE4 inhibitor specifically targeting the terminal ileum and colon for treating fibrostenotic Crohn’s disease and ulcerative colitis, addressing significant unmet medical needs.
- The issuance of the Notice of Allowance for a patent covering PALI-2108 in China bolsters the company's intellectual property portfolio in a major pharmaceutical market.
- The allowed patent covers claims on the composition of matter for PALI-2108 with a base term extending into 2045, enhancing long-term value for the company.
- Palisade Bio is advancing PALI-2108 through a Phase 1b/2a clinical trial, with multiple near-term clinical milestones anticipated to serve as potential value inflection points.
Potential Negatives
- Despite the positive announcement regarding the patent allowance, the company faces significant uncertainties related to the success of its ongoing clinical trials for PALI-2108, which could impact future valuations.
- The statement includes numerous cautionary notes regarding forward-looking statements, implying that actual results may vary and that the company is relying heavily on the successful outcome of future studies, which is not guaranteed.
- The need for additional financing to fund future operations and development raises concerns about the company's financial stability and operational viability moving forward.
FAQ
What is PALI-2108?
PALI-2108 is a novel PDE4 inhibitor aimed at treating fibrostenotic Crohn’s disease and ulcerative colitis.
What therapeutic areas does Palisade Bio focus on?
Palisade Bio focuses on developing therapeutics for autoimmune, inflammatory, and fibrotic diseases.
What is the significance of the Chinese patent for PALI-2108?
The patent allowance in China secures long-term value for PALI-2108 in a major pharmaceutical market.
How is PALI-2108 currently being evaluated?
PALI-2108 is being assessed in a Phase 1b/2a clinical trial for fibrostenotic Crohn’s disease and ulcerative colitis.
Where can I find more information about the clinical study?
More information about the clinical study can be found at clinicaltrials.gov using identifier NCT06663605.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PALI Hedge Fund Activity
We have seen 9 institutional investors add shares of $PALI stock to their portfolio, and 2 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CETERA INVESTMENT ADVISERS removed 70,006 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $47,660
- ARMISTICE CAPITAL, LLC added 39,397 shares (+37.4%) to their portfolio in Q1 2025, for an estimated $26,821
- UBS GROUP AG added 29,109 shares (+324.4%) to their portfolio in Q1 2025, for an estimated $19,817
- HRT FINANCIAL LP added 18,264 shares (+inf%) to their portfolio in Q1 2025, for an estimated $12,434
- VIRTU FINANCIAL LLC added 15,255 shares (+inf%) to their portfolio in Q1 2025, for an estimated $10,385
- GEODE CAPITAL MANAGEMENT, LLC added 14,680 shares (+146.0%) to their portfolio in Q1 2025, for an estimated $9,994
- TWO SIGMA SECURITIES, LLC added 14,153 shares (+inf%) to their portfolio in Q1 2025, for an estimated $9,635
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PALI Analyst Ratings
Wall Street analysts have issued reports on $PALI in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Brookline Capital issued a "Buy" rating on 05/13/2025
To track analyst ratings and price targets for $PALI, check out Quiver Quantitative's $PALI forecast page.
Full Release
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC),
to address significant unmet medical needs
Inflammatory Bowel Disease is a large and growing market opportunity in China, with forecasts approaching $1B in total revenues by 2030
Carlsbad, CA, July 31, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio,” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that the China National Intellectual Property Administration has issued a Notice of Allowance for a patent covering PALI-2108, the Company’s novel, locally-activated, terminal ileum and colon-targeted phosphodiesterase-4 B/D (PDE4 B/D) inhibitor being developed for fibrostenotic Crohn’s disease (FSCD) and moderate to severe ulcerative colitis (UC).
Once issued, the allowed patent titled, “ Gut Microbiota-Activated PDE4 Inhibitor Prodrug ,” will cover claims on the composition of matter for PALI-2108 in China with a base patent term currently extending into 2045, subject to extension to account for time required to fulfill requirements for regulatory approval.
“Strengthening the global intellectual property portfolio around PALI-2108 remains a priority as we continue advancing this first-in-class therapy for FSCD and UC,” said J.D. Finley, Chief Executive Officer of Palisade Bio. “This Notice of Allowance in China bolsters our ability to protect long-term value in one of the world’s largest and fastest-growing pharmaceutical markets, further supporting both our clinical and strategic objectives. We remain highly confident in the potential of PALI-2108 and are diligently executing on multiple near-term clinical milestones and expected data readouts in the next 12-18 months, each of which, if successful, would represent a major value inflection point.”
The Company is currently evaluating PALI-2108 in a Phase 1b/2a clinical trial for the treatment of FSCD and UC. For more information about the Phase 1a/b clinical study, visit clinicaltrials.gov and reference identifier NCT06663605.
About Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com .
Forward Looking Statements
This communication contains “forward-looking” statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the safety and tolerability, PK and drug release characteristics of PALI-2108 based on the Company’s preclinical studies and preliminary data from the Company’s clinical studies and indications and anticipated benefits of PALI-2108. These forward-looking statements are based upon the Company’s current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company’s forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company’s clinical trials, the timing and success of preclinical studies and clinical trials conducted by the Company, the risk that prior results, such as signals of safety, activity, or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company’s product candidates in clinical trials focused on the same or different indications; and the Company’s ability to secure additional financing to fund future operations and development of its product candidates. Additional risks and uncertainties can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 24, 2025, as well as the Company’s Quarterly Report on Form 10-Q, for the three-month period ended March 31, 2025, filed with the SEC on May 12, 2025. These forward-looking statements speak only as of the date hereof and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
[email protected]